Tamsulosyna i solifenacyna jako forma leczenia skojarzonego pacjentów z objawami ze strony dolnych dróg moczowych – wskazania oparte na zasadach evidence-based medicine oraz praktycznych doświadczeniach Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
łagodny rozrost stercza, częstomocz, parcia naglące, tamsulosyna, solifenacyna, leczenie skojarzone
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leczenie skojarzone tamsulosyną i solifenacyną jest jednym z częściej stosowanych skojarzeń lekowych u pacjentów z nasilonymi objawami z dolnych dróg moczowych w fazie napełniania. Objawy takie mogą mieć charakter wtórny do przeszkody podpęcherzowej, ale mogą być również patofizjologicznie niezależne od łagodnego rozrostu stercza. Duoterapia tamsulosyną i solifenacyną wydaje się leczeniem bezpiecznym, a z perspektywy klinicznej kluczowa pozostaje selekcja pacjenta, który odniesie największą korzyść z takiego leczenia.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Zapała, P. (2024). Tamsulosyna i solifenacyna jako forma leczenia skojarzonego pacjentów z objawami ze strony dolnych dróg moczowych – wskazania oparte na zasadach evidence-based medicine oraz praktycznych doświadczeniach. Medycyna Faktów , 17(1(62), 110-114. https://doi.org/10.24292/01.MF.0124.17
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Chapple CR, Wein AJ, Abrams P et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol. 2008; 54(3): 563-9.
2. Roosen A, Chapple CR, Dmochowski RR et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009; 56(5): 810-9.
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6): 1306-14; discussion 1314-5.
4. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009; 56(3): 534-41.
5. Lee HN, Lee KS, Kim JC et al. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Int J Clin Pract. 2015; 69(4): 444-53.
6. Athanasopoulos A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169(6): 2253-6.
7. Gacci M, Sebastianelli A, Salvi M et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015; 16(9): 60.
8. Van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013; 64(3): 398-407.
9. Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-70.
10. Roehrborn CG, Kaplan SA, Kraus SR et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008; 72(5): 1061-7; discussion 1067.
11. Drake MJ, Bowditch S, Arbe E et al. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urol. 2017; 17(1): 36.
12. Athanasopoulos A, Chapple C, Fowler C et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol. 2011; 60(1): 94-105.
13. Kaplan SA, Roehrborn CG, Abrams P et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65(4): 487-507.
14. Kim HJ, Sun HY, Choi H et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PloS One. 2017; 12(1): e0169248.
15. van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64(6): 1003-12.
16. EAU Guidelines: Management of Non-neurogenic Male LUTS. Uroweb.
17. Rees J, Foley S, Huang M et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn. 2019; 38(3): 981-9.
18. Burgio KL, Kraus SR, Johnson TM et al. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial. JAMA Intern Med. 2020; 180(3): 411-9.
19. Gong M, Dong W, Huang G et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015; 31(9): 1781-92.
20. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006; 296(19): 2319-28.
21. Drake MJ, Oelke M, Snijder R et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PloS One. 2017; 12(2): e0170726.
22. Kaplan SA, He W, Koltun WD. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol. 2013; 63(1): 158-65.
23. İlhan B, Erdoğan T, Topinková E et al.; EuGMS Task and Finish Group on FRIDs. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review. Eur Geriatr Med. 2023; 14(4): 733-46.
2. Roosen A, Chapple CR, Dmochowski RR et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009; 56(5): 810-9.
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6): 1306-14; discussion 1314-5.
4. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009; 56(3): 534-41.
5. Lee HN, Lee KS, Kim JC et al. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Int J Clin Pract. 2015; 69(4): 444-53.
6. Athanasopoulos A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003; 169(6): 2253-6.
7. Gacci M, Sebastianelli A, Salvi M et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015; 16(9): 60.
8. Van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013; 64(3): 398-407.
9. Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-70.
10. Roehrborn CG, Kaplan SA, Kraus SR et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008; 72(5): 1061-7; discussion 1067.
11. Drake MJ, Bowditch S, Arbe E et al. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urol. 2017; 17(1): 36.
12. Athanasopoulos A, Chapple C, Fowler C et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol. 2011; 60(1): 94-105.
13. Kaplan SA, Roehrborn CG, Abrams P et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011; 65(4): 487-507.
14. Kim HJ, Sun HY, Choi H et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PloS One. 2017; 12(1): e0169248.
15. van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64(6): 1003-12.
16. EAU Guidelines: Management of Non-neurogenic Male LUTS. Uroweb.
17. Rees J, Foley S, Huang M et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn. 2019; 38(3): 981-9.
18. Burgio KL, Kraus SR, Johnson TM et al. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial. JAMA Intern Med. 2020; 180(3): 411-9.
19. Gong M, Dong W, Huang G et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015; 31(9): 1781-92.
20. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006; 296(19): 2319-28.
21. Drake MJ, Oelke M, Snijder R et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASTM for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PloS One. 2017; 12(2): e0170726.
22. Kaplan SA, He W, Koltun WD. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol. 2013; 63(1): 158-65.
23. İlhan B, Erdoğan T, Topinková E et al.; EuGMS Task and Finish Group on FRIDs. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review. Eur Geriatr Med. 2023; 14(4): 733-46.